A Two-Part Phase 3 Study of LY4170156 in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

• Status: NOT_YET_RECRUITING
• Trial end date: 2031-08-01

Summary

This is a clinical study that has two parts. It is testing a potential new medicine called LY4170156 for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whose cancer no longer responds to platinum-based treatments (a type of chemotherapy). Part B looks at participants whose cancer still responds to platinum-based treatments. The researchers want to find out if LY4170156 works better than the usual treatments that doctors use now and to better understand how safe it is. Each participant's time in the study will depend on how they respond to the treatment.

• Phase: PHASE3

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborators: Asia-Pacific Gynecologic Oncology Trials Group (APGOT); European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
• Treatments: Bevacizumab; Carboplatin; Gemcitabine; liposomal doxorubicin; Paclitaxel; Topotecan